Franco M, Tapia E, Martínez F, Davila M E, Grimaldo J I, Medina K, Herrera-Acosta J
Department of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
J Am Soc Nephrol. 1999 Aug;10(8):1681-8. doi: 10.1681/ASN.V1081681.
In the hypothyroid kidney, exogenous adenosine (ADO) produces vasodilation and restores renal function to near-normal values. This study evaluates whether this response is mediated by nitric oxide synthesis stimulated by adenosine. GFR and urinary excretion of NO2-/NO3- (UNO2-/NO3-) were measured in normal (NL) and hypothyroid (HTX) rats under basal conditions and during infusion of: intra-aortic ADO, intravenously, 1,3-dipropyl-8p-sulfophenylxanthine (DPSPX), 8-cyclopentyl-1,3-dipropyl xanthine (DPCPX), N(omega)-nitro-L-arginine methylester (L-NAME) + ADO, L-NAME + PSPX, L-NAME + DPCPX, and intrarenal (IR) ADO or DPCPX + IR ADO. Intra-aortic ADO induced a fall in GFR and increased UNO2-/NO3- slightly in NL rats; in HTX rats, both GFR and UNO2-/NO3- increased significantly. DPSPX and DPCPX increased UNO2-/NO3- excretion in NL animals with minor changes in GFR; the blockers increased both GFR and UNO2-/ NO3- in HTX rats. L-NAME completely blocked the increase in NO2-/NO3- induced by ADO, DPSPX, and DPCPX. The intrarenal infusion of ADO at 1, 10, and 35 nmol/kg per min progressively decreased GFR with a slight increase in UNO2-/ NO3- in NL rats; in the HTX, GFR increased with the highest dose and UNO2-/NO3- progressively increased. DPCPX prevented the fall in GFR induced by intrarenal ADO in NL rats, with no further changes in UNO2-/NO3-; in HTX rats, intrarenal ADO under A1 blockade further increased GFR and UNO2-/NO3-. Arterial and venous ADO concentrations were lower in the HTX rats. In the HTX kidney, NO production was stimulated by ADO, most likely through activation of A2 or A3 receptors, whereas A1 receptors had an inhibitory effect. Thus, ADO receptors are involved in the regulation of kidney function in pathophysiologic conditions.
在甲状腺功能减退的肾脏中,外源性腺苷(ADO)可产生血管舒张作用,并使肾功能恢复至接近正常水平。本研究评估这种反应是否由腺苷刺激的一氧化氮合成介导。在基础条件下以及在输注以下物质期间,测量正常(NL)和甲状腺功能减退(HTX)大鼠的肾小球滤过率(GFR)和尿中NO2-/NO3-的排泄量(UNO2-/NO3-):主动脉内ADO、静脉注射1,3-二丙基-8-p-磺基苯基黄嘌呤(DPSPX)、8-环戊基-1,3-二丙基黄嘌呤(DPCPX)、N(ω)-硝基-L-精氨酸甲酯(L-NAME)+ADO、L-NAME+PSPX、L-NAME+DPCPX以及肾内(IR)ADO或DPCPX+IR ADO。主动脉内ADO使NL大鼠的GFR下降,并使UNO2-/NO3-略有增加;在HTX大鼠中,GFR和UNO2-/NO3-均显著增加。DPSPX和DPCPX使NL动物的UNO2-/NO排泄量增加,GFR有轻微变化;这些阻滞剂使HTX大鼠的GFR和UNO2-/NO3-均增加。L-NAME完全阻断了由ADO、DPSPX和DPCPX诱导的NO2-/NO3-增加。在NL大鼠中,以每分钟1、10和35 nmol/kg的速度肾内输注ADO会使GFR逐渐下降,UNO2-/NO3-略有增加;在HTX大鼠中,最高剂量时GFR增加,UNO2-/NO3-逐渐增加。DPCPX可防止NL大鼠肾内ADO诱导的GFR下降,UNO2-/NO3-无进一步变化;在HTX大鼠中,A1受体阻断下的肾内ADO进一步增加了GFR和UNO2-/NO3-。HTX大鼠的动脉和静脉ADO浓度较低。在HTX肾脏中,ADO刺激NO生成,最可能是通过激活A2或A3受体,而A1受体具有抑制作用。因此,ADO受体参与病理生理条件下的肾功能调节。